BioPharmSignal logoBioPharmSignal

Biotech News

GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF

GENFIT (GNFT)GENFITFDA / regulatory

FDA grants Orphan Drug Designation (ODD) for NTZ for ACLF, a severe condition with no approved therapies NTZ is being advanced in ACLF through its G1090N reformulation, designed to unlock its clinical potential for patients facing this life ‑ threatening condition This regulatory milestone follows

Related news

GNFTGENFIT2026-01-06 17:13 EST

GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N

GNFTGENFIT2026-04-20 16:00 EST

GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)

View all latest news

GENFIT

Liver-Disease Therapeutics and Diagnostics GENFIT develops therapies and diagnostic technologies for liver diseases. Its portfolio combines commercial economics from a partnered product with internal programs in cholangiocarcinoma and acute-on-chronic liver failure. Iqirvo Economics GENFIT receives milestones and royalties from Ipsen’s...

Recent company news

GNFTGENFIT2026-08-03 14:32 EST

GENFIT Answers its Investors – Episode #3 - August 3, 2026

GNFTGENFIT2026-07-08 16:00 EST

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GNFTGENFIT2026-07-02 16:05 EST

GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH

GNFTGENFIT2026-06-23 16:00 EST

GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

GNFTGENFIT2026-06-15 16:10 EST

GENFIT: June 15, 2026 Combined Shareholders Meeting Results

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States